Thanks, that's an interesting insight into the dropoff rate for these ideas. Do you have an opinion on what the bottleneck is? Volume of ideas, length of testing, or perhaps flawed approach in general?
This is the bottleneck for one company. We have many companies this size doing the same thing.
The issue is large companies (novartis/BMS) sometimes sit on compounds and refuse to develop because they think it may not be worth it, may think a certain disease (read market) is saturated, or they may be waiting for the 'right time'. It can be frustrating.
Smaller companies have 2-3 compounds which they actively work to develop but most of them end up getting acquired by the big fish.
The extreme complexity of biology. There's no substitute to just trying things and seeing if they work, because you will never understand what's going on beforehand.
The issue is large companies (novartis/BMS) sometimes sit on compounds and refuse to develop because they think it may not be worth it, may think a certain disease (read market) is saturated, or they may be waiting for the 'right time'. It can be frustrating.
Smaller companies have 2-3 compounds which they actively work to develop but most of them end up getting acquired by the big fish.